Mobile Trading

WINDLAS BIOTECH LTD.

NSE : WINDLASBSE : 543329ISIN CODE : INE0H5O01029Industry : Pharmaceuticals & DrugsHouse : Private
BSE758.10-12.55 (-1.63 %)
PREV CLOSE ( ) 770.65
OPEN PRICE ( ) 766.15
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2339
TODAY'S LOW / HIGH ( )750.00 766.65
52 WK LOW / HIGH ( )667.3 1175.2
Select year
ParticularsMar2025Mar2024Mar2023Mar2022Mar2021
Operational & Financial Ratios
   Earnings Per Share (Rs)29.1027.9820.3717.4824.70
   CEPS(Rs)42.4534.4426.2823.0515.67
   DPS(Rs)5.805.504.003.500.00
   Book NAV/Share(Rs)238.80213.99190.89180.31310.59
   Tax Rate(%)23.5324.5225.2716.4128.38
Margin Ratios
   Core EBITDA Margin(%)12.3812.3911.7411.2512.79
   EBIT Margin(%)11.0712.3911.2710.085.39
   Pre Tax Margin(%)10.5012.2211.129.785.08
   PAT Margin (%)8.039.228.318.173.64
   Cash Profit Margin (%)11.7111.3510.7210.786.67
Performance Ratios
   ROA(%)8.8010.108.399.704.91
   ROE(%)12.9013.7810.7612.877.62
   ROCE(%)17.1218.3414.3914.889.85
   Asset Turnover(x)1.101.091.011.191.35
   Sales/Fixed Asset(x)2.452.692.872.683.24
   Working Capital/Sales(x)2.762.432.211.624.24
Efficiency Ratios
   Fixed Capital/Sales(x)0.410.370.350.370.31
   Receivable days72.8173.2280.9774.4961.18
   Inventory Days34.4839.6147.4739.2438.74
   Payable days120.16106.8992.1864.7885.92
Valuation Parameters
   PER(x)35.7818.3111.0612.020.00
   PCE(x)24.5314.888.579.110.00
   Price/Book(x)4.362.391.181.170.00
   Yield(%)0.561.071.781.67
   EV/Net Sales(x)2.891.640.870.750.02
   EV/Core EBITDA(x)19.5611.296.365.920.11
   EV/EBIT(x)26.0713.237.727.450.29
   EV/CE(x)4.122.301.110.720.02
   M Cap / Sales2.871.690.920.980.00
Growth Ratio
   Net Sales Growth(%)20.4322.9710.128.9630.03
   Core EBITDA Growth(%)22.3530.5618.712.3331.47
   EBIT Growth(%)7.6035.2223.08104.00-15.31
   PAT Growth(%)4.8236.5111.91144.63-3.97
   EPS Growth(%)4.0137.3516.55-29.23-2.35
Financial Stability Ratios
   Total Debt/Equity(x)0.050.000.000.020.16
   Current Ratio(x)2.112.512.924.062.08
   Quick Ratio(x)1.782.152.303.441.64
   Interest Cover(x)19.2070.7773.3833.1617.85
   Total Debt/Mcap(x)0.010.000.000.01

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER
© 2018 Ratnakar Securities Pvt. Ltd. All rights reserved.
Designed, Developed & Content Powered by  Accord Fintech Pvt. Ltd.
CLOSE X

Filing complaints on SCORES Easy & quick

  • > Register on SCORES portal (link:https://scores.gov.in)
  • > Mandatory details for filing complaints on SCORES
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • > Benefits:
    • Effective communication
    • Speedy redressal of the grievances
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.